Kiora Pharmaceuticals, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 49721T507 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Nantahala Capital Management, LLC 13G/A	10.0%	491,889	13G/A	8/14/2026 Event 6/30/2026
Nantahala Capital Management, LLC	10.0%	491,889
Wilmot B. Harkey	10.0%	491,889
Daniel Mack	10.0%	491,889
Perceptive Advisors LLC 13G	10.0%	442,387	13G	8/10/2026 Event 4/6/2026
Perceptive Advisors LLC	10.0%	442,387
Joseph Edelman	10.0%	442,387
Perceptive Life Sciences Master Fund, Ltd.	10.0%	442,387
Alyeska Investment Group, L.P. 13G	10.0%	394,668	13G	5/15/2026 Event 3/31/2026
Alyeska Investment Group, L.P.	10.0%	394,668
Alyeska Fund GP, LLC	10.0%	394,668
Anand Parekh	10.0%	394,668
ADAR1 Capital Management, LLC 13G/A	9.9%	475,378	13G/A	8/14/2026 Event 6/30/2026
ADAR1 Capital Management, LLC	9.9%	472,721
ADAR1 Capital Management GP, LLC	9.9%	475,378
Daniel Schneeberger	9.9%	472,721
Baselake Partners, LP 13G	5.8%	257,500	13G	9/17/2026 Event 9/10/2026
Baselake Partners, LP	5.8%	257,500
Baselake Management, LLC	5.8%	257,500
David Paolella	5.8%	257,500
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Orin Hirschman 13G/A	4.9%	192,984	13G/A	1/29/2026 Event 12/31/2025
Orin Hirschman	4.9%	192,984
AIGH Capital Management LLC	4.9%	192,984
Nantahala Capital Partners Limited Partnership 13G/A	3.4%	148,736	13G/A	5/15/2026 Event 3/31/2026
Goldman Sachs Group Inc 13G/A	0%	130	13G/A	2/12/2025 Event 12/31/2024
The Goldman Sachs Group, Inc.	0%	130
Goldman Sachs & Co. LLC	0%	130

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	22	1.11 M	$2.91 M	$0
2026 Q1	18	339 k	$655 k	$0
2025 Q4	19	707 k	$1.39 M	$0
2025 Q3	17	616 k	$1.71 M	$0
2025 Q2	17	932 k	$2.68 M	$0
2025 Q1	19	1.29 M	$3.87 M	$0
2024 Q4	17	1.26 M	$4.16 M	$0
2024 Q3	19	1.21 M	$4.44 M	$0
2024 Q2	18	966 k	$4.06 M	$0